Our placebo-controlled study demonstrated that MgO was effective treatment for improving defecation status and shortened CTT in Japanese CC patients with mild to moderate symptoms. MgO significantly improved the Japanese version of the patient assessment of constipation quality of life ( P = 0.003). In addition, MgO significantly improved Bristol stool form scale changes ( P < 0.001) and significantly improved CTT compared to the placebo group ( P < 0.001). However, MgO did not significantly improved response rates of CSBM compared to placebo ( P = 0.76). MgO significantly improved SBM changes compared to placebo ( P = 0.002). The primary endpoint was met by 25.0% of placebo vs 70.6% of MgO group ( P = 0.015). One patient failed to complete the medication regimen and was omitted from analysis: data from 16 placebo and 17 MgO patients were analyzed. Secondary endpoints were changes from baseline in spontaneous bowel movement (SBM), response rates of complete spontaneous bowel movement (CSBM), stool form, colonic transit time (CTT), abdominal symptom, and quality of life. Primary endpoint was overall improvement over the 4-week study period. Thirty-four female patients with mild to moderate constipation were randomly assigned to either placebo (n = 17) or MgO group (n = 17) 0.5 g × 3/day for 28 days. We conducted a randomized, double-blind placebo-controlled study. The aim of this study is to evaluate its therapeutic effects of MgO in Japanese CC patients. Magnesium oxide (MgO) has been frequently used as a treatment for chronic constipation (CC) since the 1980s in Japan.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |